Literature DB >> 12205285

Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: a preliminary study.

Penelope A Demas1, Mayris P Webber, Ellie E Schoenbaum, Jeremy Weedon, Janis McWayne, Elizabeth Enriquez, Mahrukh Bamji, Genevieve Lambert, Donald M Thea.   

Abstract

OBJECTIVE: To describe the extent of adherence to the recommended neonatal zidovudine (ZDV) regimen administered to infants who have been exposed to the human immunodeficiency virus (HIV) to prevent mother-to-child transmission of HIV and to determine which maternal factors are associated with compliance.
METHODS: HIV-infected women (n = 87) who were participating in a larger study of perinatal transmission at 3 inner-city New York City hospitals were interviewed 2 to 6 weeks' postpartum to assess adherence to neonatal prophylaxis, social support, social network factors, and depression. In addition, plasma samples of 45 of their infants were assayed for ZDV levels.
RESULTS: A majority of women (71%) administered all of the prescribed 4 daily doses in the previous week, as measured by interview; self-reported adherence was not associated with any maternal characteristics. In contrast, poor adherence, as measured by lower infant ZDV plasma levels, was associated with asymptomatic HIV illness in the mother and having 2 or more other children; good adherence, as indicated by higher ZDV levels, was associated with the presence of a maternal social support network, disclosure of HIV infection, and mothers' adherence to their own ZDV regimens during pregnancy. In multivariate regression analyses, maternal asymptomatic status (beta = -0.40) was associated with lower infant ZDV levels, and maternal adherence during pregnancy (beta = 0.37) was associated with higher levels.
CONCLUSIONS: Women who are HIV asymptomatic and lack a social support network are more likely not to comply with the recommended neonatal prophylactic regimen of antiretroviral therapy. Future studies should address the prenatal period and social network factors, such as disclosure of serostatus, and the custody of other children.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12205285      PMCID: PMC4561177          DOI: 10.1542/peds.110.3.e35

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  22 in total

1.  Trends in perinatal transmission of HIV/AIDS in the United States.

Authors:  M L Lindegren; R H Byers; P Thomas; S F Davis; B Caldwell; M Rogers; M Gwinn; J W Ward; P L Fleming
Journal:  JAMA       Date:  1999-08-11       Impact factor: 56.272

2.  Update: HIV counseling and testing using rapid tests--United States, 1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-03-27       Impact factor: 17.586

3.  A longitudinal study of psychological distress in a cohort of gay men. Effects of social support and coping strategies.

Authors:  J B Lackner; J G Joseph; D G Ostrow; R C Kessler; S Eshleman; C B Wortman; K O'Brien; J P Phair; J Chmiel
Journal:  J Nerv Ment Dis       Date:  1993-01       Impact factor: 2.254

4.  Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours.

Authors:  D Moodley; K Pillay; K Naidoo; J Moodley; M A Johnson; K H Moore; P N Mudd; G E Pakes
Journal:  J Clin Pharmacol       Date:  2001-07       Impact factor: 3.126

5.  Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1.

Authors:  D C Watson; J J Farley
Journal:  Pediatr Infect Dis J       Date:  1999-08       Impact factor: 2.129

Review 6.  Prevention of HIV infection in children.

Authors:  M Bulterys; M G Fowler
Journal:  Pediatr Clin North Am       Date:  2000-02       Impact factor: 3.278

7.  After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group.

Authors:  E R Cooper; R P Nugent; C Diaz; J Pitt; C Hanson; L A Kalish; H Mendez; C Zorrilla; R Hershow; J Moye; V Smeriglio; M G Fowler
Journal:  J Infect Dis       Date:  1996-12       Impact factor: 5.226

8.  Improved birth outcomes associated with enhanced Medicaid prenatal care in drug-using women infected with the human immunodeficiency virus.

Authors:  C J Newschaffer; J Cocroft; W W Hauck; T Fanning; B J Turner
Journal:  Obstet Gynecol       Date:  1998-06       Impact factor: 7.661

9.  Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.

Authors:  F D Boucher; J F Modlin; S Weller; A Ruff; M Mirochnick; S Pelton; C Wilfert; R McKinney; M J Crain; M M Elkins
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

10.  Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus.

Authors:  N A Wade; G S Birkhead; B L Warren; T T Charbonneau; P T French; L Wang; J B Baum; J M Tesoriero; R Savicki
Journal:  N Engl J Med       Date:  1998-11-12       Impact factor: 91.245

View more
  9 in total

1.  Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacy.

Authors:  Penelope A Demas; Donald M Thea; Jeremy Weedon; Janis McWayne; Mahrukh Bamji; Genevieve Lambert; Ellie E Schoenbaum
Journal:  Women Health       Date:  2005

Review 2.  Parenting Among Adolescents and Young Adults with Human Immunodeficiency Virus Infection in the United States: Challenges, Unmet Needs, and Opportunities.

Authors:  Kendra Hatfield-Timajchy; Jennifer L Brown; Lisa B Haddad; Rana Chakraborty; Athena P Kourtis
Journal:  AIDS Patient Care STDS       Date:  2016-07       Impact factor: 5.078

Review 3.  Facilitating adherence to highly active antiretroviral therapy in children with HIV infection: what are the issues and what can be done?

Authors:  Emanuele Pontali
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

4.  Gender differences in factors associated with adherence to antiretroviral therapy.

Authors:  Karina M Berg; Penelope A Demas; Andrea A Howard; Ellie E Schoenbaum; Marc N Gourevitch; Julia H Arnsten
Journal:  J Gen Intern Med       Date:  2004-11       Impact factor: 5.128

Review 5.  Prevention of mother-to-child transmission of HIV type 1: the role of neonatal and infant prophylaxis.

Authors:  Stacey A Hurst; Kristie E Appelgren; Athena P Kourtis
Journal:  Expert Rev Anti Infect Ther       Date:  2015-02       Impact factor: 5.091

6.  Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study.

Authors:  Daniel J Merenstein; Michael F Schneider; Christopher Cox; Rebecca Schwartz; Kathleen Weber; Esther Robison; Monica Gandhi; Jean Richardson; Michael W Plankey
Journal:  Pediatrics       Date:  2008-04       Impact factor: 7.124

7.  Medicaid patients at high risk for frequent hospital admission: real-time identification and remediable risks.

Authors:  Maria C Raven; John C Billings; Lewis R Goldfrank; Eric D Manheimer; Marc N Gourevitch
Journal:  J Urban Health       Date:  2008-12-12       Impact factor: 3.671

Review 8.  Adherence to high activity antiretrovial therapy (HAART) in pediatric patients infected with HIV: issues and interventions.

Authors:  Chirag A Shah
Journal:  Indian J Pediatr       Date:  2007-01       Impact factor: 5.319

9.  Adherence to antiretroviral prophylaxis during early infancy in Latin America.

Authors:  Cristina B Hofer; D Robert Harris; Mariza C Saavedra; Jessica E Haberer; Juliana Romeiro; Marisa M Mussi-Pinhata; Erica Stankievich; Ivete M Gomes; Regis Kreitchmann; Jennifer S Read
Journal:  Braz J Infect Dis       Date:  2013-05-13       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.